C/O ADMA BIOLOGICS, INC., RAMSEY, NJ
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces FDA Approval of ASCENIV™ for Pediatric Patients
Annual Report to Security Holders
Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Investor Presentation
Financial Results, Press Release
Q1
FY 2024
Q3
Q2
Notice of Late Filing for Annual Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Certification of Termination of Registration of a Class of Security
Registration of Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence